Virax Biolabs Group Ltd
NASDAQ:VRAX
Balance Sheet
Balance Sheet Decomposition
Virax Biolabs Group Ltd
Virax Biolabs Group Ltd
Balance Sheet
Virax Biolabs Group Ltd
| Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
9
|
4
|
4
|
|
| Cash |
0
|
0
|
0
|
9
|
4
|
4
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Current Assets |
0
|
0
|
0
|
10
|
4
|
5
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
1
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
0
+100%
|
0
+25%
|
10
+19 525%
|
5
-44%
|
6
+17%
|
|
| Liabilities | |||||||
| Accounts Payable |
0
|
0
|
1
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
1
|
0
|
1
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
-36%
|
1
+48%
|
1
-33%
|
0
-83%
|
1
+524%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1
|
1
|
1
|
9
|
5
|
6
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
1
+39%
|
1
-49%
|
9
N/A
|
5
-41%
|
6
+6%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
+100%
|
0
+25%
|
10
+19 525%
|
5
-44%
|
6
+17%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
11
|
11
|
11
|
2
|
3
|
4
|
|